目的 研究肾炎康复片联合他克莫司胶囊治疗肾病综合征的临床疗效。方法 选取2016年8月—2018年8月三二〇一医院收治的肾病综合征患者60例为研究对象，将所有患者采用照抽签方式分为对照组和治疗组，每组各30例。对照组患者口服他克莫司胶囊，0.05 mg/(kg·d)，保持他克莫司血药浓度为10 ng/mL；治疗组在对照组治疗的基础上口服肾炎康复片，5片/次，3次/d。两组持续治疗2个月。观察两组患者的临床疗效，比较两组治疗前后的肾功能指标和血清炎症因子水平。结果 治疗后，治疗组总有效率为93.33%，显著高于对照组的76.67%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血浆白蛋白（ALB）水平显著升高，24 h尿蛋白定量（24 h Pro）、血肌酐（Scr）和血尿素氮（BUN）水平显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组肾功能指标显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者C-反应蛋白（CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清炎症因子水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 肾炎康复片联合他克莫司胶囊治疗肾病综合征具有较好的临床疗效，可显著改善患者肾功能，安全性较高，具有一定的临床推广应用价值。

objective To study the clinical effect of Shenyan Kangfu Tablets combined with Tacrolimus Capsules in treatment of nephrotic syndrome. Methods Patients (60 cases) with nephrotic syndrome in San Er Ling Yi Hospital from August 2016 to August 2018 were divided into control and treatment groups by lottery, and each group had 30 cases. Patients in the control group were po administered with Tacrolimus Capsules, 0.05 mg/(kg·d), and the blood concentration of tacrolimus was maintained at 10 ng/mL. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of control group, 5 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the renal function indexes and serum inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 93.33%, which was significantly higher than 76.67% in the control group, and there were differences between two groups (P < 0.05). After treatment, ALB levels in two groups were significantly increased, but the 24 h Pro, Scr, and BUN levels were decreased, and the difference was statistically significant in the same group (P< 0.05). After treatment, the renal function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the levels of CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). After treatment, serum inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). Conclusion Shenyan Kangfu Tablets combined with Tacrolimus Capsules has a good clinical effect in treatment of nephrotic syndrome, can significantly improve the renal function, with high safety, which has a certain clinical application value.